CTOs on the Move

SignalChem Lifesciences

www.signalchemlifesciences.com

 
SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases.   The Company has a robust kinase platform encompassing 450 kinase targets and assays for the development and commercialization of unique therapies in many diseases.   This vast resource empowers SLC’s scientists to identify novel drug candidates against kinase targets of interest.   Another key part of SLC’s kinase drug development platform is KineCore, a kinase focused small molecule library that was designed and assembled in-house.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Celsius Therapeutics

Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single-cell RNA sequencing and genomic analysis to develop life-changing medicines. Our common goal is to markedly improve human health by integrating data, experience and insight. Located in Cambridge, Mass., our environment is rigorous, fast-paced and collaborative, bringing together passionate individuals who are making an impact. We inspire creativity and discovery by embracing an open culture that fosters innovation, teamwork and excellence. We are committed to attracting and retaining the best talent, and we believe that our growth and success will be driven by those who are inspired by our mission and share our values. If you`re curious, collaborative and relentless about making a difference in the lives of patients, join us!

GRACE NETWORK

GRACE NETWORK is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ziemer USA INC

Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Thrasos Therapeutics

Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease

hhoaltd

hhoaltd is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.